Biogen

Biogen Inc., founded in 1978 and based in Cambridge, Massachusetts, is a pioneering global biotechnology company that focuses exclusively on discovering, developing, and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. As one of the earliest biotechnology companies, Biogen has built a legacy of scientific leadership in neuroscience, tackling some of the most complex and devastating conditions known to medicine, including Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS).

The company transformed the MS treatment landscape with its industry-leading portfolio of therapies, including Tecfidera and Tysabri. Biogen also developed Spinraza, the first approved treatment for SMA, profoundly altering the trajectory of this fatal genetic disease. In recent years, Biogen has been at the vanguard of Alzheimer’s disease research, co-developing groundbreaking amyloid-targeting therapies that represent significant milestones in neurodegenerative care.

The organization operates cutting-edge research laboratories and boasts some of the world’s most advanced biologic manufacturing facilities, ensuring the safe and reliable production of highly complex macromolecular therapies. Biogen’s research philosophy is deeply rooted in genetic insights and biomarker-driven clinical development, allowing for more targeted and effective therapeutic interventions. The company frequently collaborates with leading academic institutions, biotech startups, and major pharmaceutical companies to accelerate the pace of innovation.

Beyond drug development, Biogen is deeply committed to supporting patient communities through extensive advocacy and access programs. Driven by a mission to defeat neurological diseases, Biogen continues to invest heavily in its robust pipeline, pushing the boundaries of neuroscience to deliver life-changing treatments to patients worldwide.